Literature DB >> 33658355

Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates.

Nicole Darricarrère1, Yu Qiu1, Masaru Kanekiyo2, Adrian Creanga2, Rebecca A Gillespie2, Syed M Moin2, Jacqueline Saleh1, Jose Sancho1, Te-Hui Chou1, Yanfeng Zhou1, Ruijun Zhang1, Shujia Dai1, Anthony Moody3, Kevin O Saunders3, Michelle C Crank2, John R Mascola2, Barney S Graham2, Chih-Jen Wei4, Gary J Nabel4.   

Abstract

Seasonal influenza vaccines confer protection against specific viral strains but have restricted breadth that limits their protective efficacy. The H1 and H3 subtypes of influenza A virus cause most of the seasonal epidemics observed in humans and are the major drivers of influenza A virus-associated mortality. The consequences of pandemic spread of COVID-19 underscore the public health importance of prospective vaccine development. Here, we show that headless hemagglutinin (HA) stabilized-stem immunogens presented on ferritin nanoparticles elicit broadly neutralizing antibody (bnAb) responses to diverse H1 and H3 viruses in nonhuman primates (NHPs) when delivered with a squalene-based oil-in-water emulsion adjuvant, AF03. The neutralization potency and breadth of antibodies isolated from NHPs were comparable to human bnAbs and extended to mismatched heterosubtypic influenza viruses. Although NHPs lack the immunoglobulin germline VH1-69 residues associated with the most prevalent human stem-directed bnAbs, other gene families compensated to generate bnAbs. Isolation and structural analyses of vaccine-induced bnAbs revealed extensive interaction with the fusion peptide on the HA stem, which is essential for viral entry. Antibodies elicited by these headless HA stabilized-stem vaccines neutralized diverse H1 and H3 influenza viruses and shared a mode of recognition analogous to human bnAbs, suggesting that these vaccines have the potential to confer broadly protective immunity against diverse viruses responsible for seasonal and pandemic influenza infections in humans.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2021        PMID: 33658355     DOI: 10.1126/scitranslmed.abe5449

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  16 in total

1.  Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus.

Authors:  Maya Sangesland; Alba Torrents de la Peña; Seyhan Boyoglu-Barnum; Larance Ronsard; Faez Amokrane Nait Mohamed; Thalia Bracamonte Moreno; Ralston M Barnes; Daniel Rohrer; Nils Lonberg; Musie Ghebremichael; Masaru Kanekiyo; Andrew Ward; Daniel Lingwood
Journal:  Immunity       Date:  2022-08-10       Impact factor: 43.474

2.  A Hemagglutinin Stem Vaccine Designed Rationally by AlphaFold2 Confers Broad Protection against Influenza B Infection.

Authors:  Dian Zeng; Jiabao Xin; Kunyu Yang; Shuxin Guo; Qian Wang; Ying Gao; Huiqing Chen; Jiaqi Ge; Zhen Lu; Limin Zhang; Junyu Chen; Yixin Chen; Ningshao Xia
Journal:  Viruses       Date:  2022-06-14       Impact factor: 5.818

Review 3.  Antibodies to combat viral infections: development strategies and progress.

Authors:  Giuseppe Pantaleo; Bruno Correia; Craig Fenwick; Victor S Joo; Laurent Perez
Journal:  Nat Rev Drug Discov       Date:  2022-06-20       Impact factor: 112.288

4.  SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

Authors:  M Gordon Joyce; Wei-Hung Chen; Rajeshwer S Sankhala; Agnes Hajduczki; Paul V Thomas; Misook Choe; William Chang; Caroline E Peterson; Elizabeth Martinez; Elaine B Morrison; Clayton Smith; Aslaa Ahmed; Lindsay Wieczorek; Alexander Anderson; Rita E Chen; James Brett Case; Yifan Li; Therese Oertel; Lorean Rosado; Akshaya Ganesh; Connor Whalen; Joshua M Carmen; Letzibeth Mendez-Rivera; Christopher Karch; Neelakshi Gohain; Zuzana Villar; David McCurdy; Zoltan Beck; Jiae Kim; Shikha Shrivastava; Ousman Jobe; Vincent Dussupt; Sebastian Molnar; Ursula Tran; Chandrika B Kannadka; Michelle Zemil; Htet Khanh; Weimin Wu; Matthew A Cole; Debra K Duso; Larry W Kummer; Tricia J Lang; Shania E Muncil; Jeffrey R Currier; Shelly J Krebs; Victoria R Polonis; Saravanan Rajan; Patrick M McTamney; Mark T Esser; William W Reiley; Morgane Rolland; Natalia de Val; Michael S Diamond; Gregory D Gromowski; Gary R Matyas; Mangala Rao; Nelson L Michael; Kayvon Modjarrad
Journal:  bioRxiv       Date:  2021-05-10

Review 5.  Influenza vaccines: Past, present, and future.

Authors:  Yun-Hee Kim; Kee-Jong Hong; Hun Kim; Jae-Hwan Nam
Journal:  Rev Med Virol       Date:  2021-05-04       Impact factor: 11.043

6.  SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

Authors:  M Gordon Joyce; Wei-Hung Chen; Rajeshwer S Sankhala; Agnes Hajduczki; Paul V Thomas; Misook Choe; Elizabeth J Martinez; William C Chang; Caroline E Peterson; Elaine B Morrison; Clayton Smith; Rita E Chen; Aslaa Ahmed; Lindsay Wieczorek; Alexander Anderson; James Brett Case; Yifan Li; Therese Oertel; Lorean Rosado; Akshaya Ganesh; Connor Whalen; Joshua M Carmen; Letzibeth Mendez-Rivera; Christopher P Karch; Neelakshi Gohain; Zuzana Villar; David McCurdy; Zoltan Beck; Jiae Kim; Shikha Shrivastava; Ousman Jobe; Vincent Dussupt; Sebastian Molnar; Ursula Tran; Chandrika B Kannadka; Sandrine Soman; Caitlin Kuklis; Michelle Zemil; Htet Khanh; Weimin Wu; Matthew A Cole; Debra K Duso; Larry W Kummer; Tricia J Lang; Shania E Muncil; Jeffrey R Currier; Shelly J Krebs; Victoria R Polonis; Saravanan Rajan; Patrick M McTamney; Mark T Esser; William W Reiley; Morgane Rolland; Natalia de Val; Michael S Diamond; Gregory D Gromowski; Gary R Matyas; Mangala Rao; Nelson L Michael; Kayvon Modjarrad
Journal:  Cell Rep       Date:  2021-12-08       Impact factor: 9.995

Review 7.  Protein engineering strategies for rational immunogen design.

Authors:  Timothy M Caradonna; Aaron G Schmidt
Journal:  NPJ Vaccines       Date:  2021-12-17       Impact factor: 7.344

Review 8.  B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat.

Authors:  Jenna J Guthmiller; Henry A Utset; Patrick C Wilson
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048

Review 9.  Animal Models for Influenza Research: Strengths and Weaknesses.

Authors:  Thi-Quyen Nguyen; Rare Rollon; Young-Ki Choi
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

10.  Engineering an Antibody V Gene-Selective Vaccine.

Authors:  Larance Ronsard; Ashraf S Yousif; Julianne Peabody; Vintus Okonkwo; Pascal Devant; Alemu Tekewe Mogus; Ralston M Barnes; Daniel Rohrer; Nils Lonberg; David Peabody; Bryce Chackerian; Daniel Lingwood
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.